Image Gently and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) created the «Go With the Guidelines» awareness campaign to encourage community hospitals, academic hospitals and clinics to observe standardized guidelines on radiopharmaceutical
dose for pediatric patients.
Not exact matches
The company's lead product candidate, dilanubicel (NLA101), is currently being evaluated in two ongoing Phase 2 clinical trials in adult and
pediatric patients with hematologic malignancies undergoing an allogeneic transplant and adult
patients receiving high
dose chemotherapy
for Acute Myeloid Leukemia.
Choosing optimal IGRT regimens that spare healthy tissue and organs is a particular concern
for pediatric patients to help prevent potential late effects associated with the distribution of the radiation
dose and the total radiation
dose the
patient receives.
Five consortium institutions cited image quality as the most important consideration when using IGRT
for pediatric patients; one facility reported
dose minimization as the primary consideration; and one facility reported both considerations were of equal importance.
Four institutions used a different IGRT
dose protocol
for pediatric patients than
for adult
patients.
The framework allowing physicians and imaging developers to tailor the precise radiation
dose to achieve a quantitative target of image quality
for pediatric patients» care has been hailed as «a big step forward» by editors of the Journal of Medical Imaging.
The position paper, «Radiation Safety in Children with Congenital and Acquired Heart Disease: A Scientific Position Statement on Multimodality
Dose Optimization from the Image Gently Alliance,» provides cardiologists, radiologists, pediatricians and internal medicine physicians guidance
for treating
pediatric patients with congenital and acquired heart disease (CAHD).
Traditional treatment of
pediatric APL has included high
doses of anthracycline, increasing
patient's risk
for cardiac toxicity.
Arsenic trioxide (ATO) consolidation was well tolerated in
pediatric patients with acute promyelocytic leukemia (APL) and allowed
for significant reductions in cumulative anthracycline
doses, according to the results of the Children's Oncology Group AAML0631 trial published in the Journal of Clinical Oncology.
Arsenic trioxide consolidation was well tolerated in
pediatric patients with acute promyelocytic leukemia and allowed
for significant reductions in cumulative anthracycline
doses.
The pharmacist is responsible
for the reviewing, compounding, dispensing and monitoring of medication therapy
for infants,
pediatric and adolescent
patients which includes
dosing variations, nutritional needs and disease states associated with the various age groups.